BeyondSpring (BYSI) Enterprise Value (2015 - 2026)
BeyondSpring (BYSI) posted Enterprise Value of -$3.7 million for Q1 2026, up 15.03% sequentially from -$4.4 million in Q4 2025, and down 152.42% YoY from $7.1 million in Q1 2025.
BeyondSpring (BYSI) Enterprise Value (2015 - 2026) Analysis & Trends
BeyondSpring has reported Enterprise Value for 12 years, with the latest figure at -$3.7 million in Q1 2026.
- Quarterly Enterprise Value fell 152.42% year-over-year to -$3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.7 million (down 152.42% YoY) and the FY2025 annual result came in at -$4.4 million, down 128.41% from the prior year.
- Enterprise Value grew to -$3.7 million in Q1 2026 per BYSI's latest filing, from -$4.4 million in the prior quarter.
- Over five years, Enterprise Value peaked at $15.5 million in Q4 2024 and troughed at -$41.3 million in Q2 2022.
- A 5-year average of -$6.2 million and a median of -$3.5 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2026: Enterprise Value jumped 546.23% in 2024, then sank 152.42% in 2026.
- Over 5 years, Enterprise Value stood at -$26.2 million in 2022, then jumped by 86.78% to -$3.5 million in 2023, then surged by 546.23% to $15.5 million in 2024, then plunged by 128.41% to -$4.4 million in 2025, then climbed by 15.03% to -$3.7 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$3.7 million, -$4.4 million, and -$768000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | -10.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.82 Mn |
| Mar 31, 2026 | -3.73 Mn |
| Dec 31, 2025 | -4.39 Mn |
| Sep 30, 2025 | -768,000.00 |
| Jun 30, 2025 | 2.87 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | 15.45 Mn |
| Jun 30, 2024 | -2.09 Mn |
| Dec 31, 2023 | -3.46 Mn |
| Jun 30, 2023 | -11.75 Mn |
| Dec 31, 2022 | -26.19 Mn |
| Jun 30, 2022 | -41.26 Mn |
| Dec 31, 2021 | -66.91 Mn |
| Sep 30, 2021 | -114.41 Mn |
| Jun 30, 2021 | -71.05 Mn |
| Mar 31, 2021 | -88.81 Mn |
| Dec 31, 2020 | -107.85 Mn |
| Sep 30, 2020 | -36.32 Mn |
| Jun 30, 2020 | -42.92 Mn |
| Mar 31, 2020 | -29.00 Mn |